ArticleChinese medicine2025
Amygdalin regulated vasoactive intestinal peptide receptor to protect alveolar epithelial barrier against lung injury induced by influenza a virus.
Article in Chinese medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- A visualization analysis of Traditional Chinese Medicine for influenza prevention and treatment: advances, hotspots, and future trends.Frontiers in medicine · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundBitter apricot kernel is a common traditional Chinese medicine used for lung diseases. Previous studies showed that Xuanbai-Chengqi decoction (XCD) containing bitter apricot kernel protected the alveolar and intestinal barriers in influenza-infected mice. However, the specific contribution of bitter apricot kernel and its active substances in viral pneumonia remain unclear. PURPOSE: This study aimed to identify the main active ingredient in bitter apricot kernel and investigate its mechanism in protecting the alveolar epithelial barrier in viral pneumonia.
methodBitter apricot kernel was evaluated based on the efficacy differences between XCD and XCD without bitter apricot kernel. Amygdalin was identified through in vitro activity tests and verified in vivo. Immunohistochemistry, RT-qPCR, and WB were used to assess barrier protection and anti-inflammatory effects. The molecular mechanisms were explored using SPR/LC/MS and validated experimentally.
resultRemoving bitter apricot kernel significantly weakened XCD's protective effect in influenza A virus-infected mice. Amygdalin showed anti-inflammatory, anti-hypoxia anti-influenza virus activities, and promoted endothelial cell migration in vitro. Amygdalin at 100 mg/kg effectively mitigated pulmonary injury and attenuated excessive inflammatory responses by regulating IL-6 and IL-10 in IAV-infected murine models. Oseltamivir is more effective than amygdalin in inhibiting the replication of influenza viruses and upregulating the expression level of IL-10. Amygdalin protected the alveolar barrier by restoring alveolar type II cells (AT2) and promoting alveolar regeneration, while upregulating surfactant protein A (SP-A) and aquaporin protein-5 (AQP5). Amygdalin bound selectively to vasoactive intestinal peptide receptor 1 (VIPR1) thereby upregulating cyclic adenosine monophosphate (cAMP) levels and the protein expression levels of Protein kinase A (PKA) and Phosphor-protein kinase A (p-PKA).
conclusionAmygdalin is the key bioactive component of bitter apricot kernel, which exhibits protective effects in an IAV-induced pneumonia mouse model by activating the cAMP/PKA/p-PKA signaling cascade and recapitulating the biological effects of vasoactive intestinal peptide (VIP).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.